Spero Therapeutics Inc to Host a Key Opinion Leader Call on Oral Tebipenem HBr for the Treatment of Complicated Urinary Tract Infections Transcript
Greetings, and welcome to today's KOL call titled Oral Tebipenem HBr for the Treatment of Complicated Urinary Tract Infections, hosted by Spero Therapeutics. (Operator Instructions) As a reminder, this conference call is being recorded.
I would now like to turn the conference over to your host, Sharon Klahre, Head of Investor Relations at Spero Therapeutics. Thank you. You may begin.
Great. Thank you, operator, and thank you all for participating in today's investor event with Dr. Keith Kaye, who will speak about the complicated urinary tract infection and his views on the unmet medical need. Following his presentation, Dr. David Melnick, Chief Medical Officer at Spero, will present on the ADAPT-PO trial; and Cristina Larkin, Chief Operating Officer, will present on the potential commercial opportunity for tebipenem HBr, if approved.
Before we begin, I'd like to remind you that some of the information contained in Spero's corporate presentation and on this
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
